无高危特征头颈癌辅助全身治疗的趋势与意义
该回顾性队列研究基于2010至2019年美国国家癌症数据库,分析接受手术和术后放疗的黏膜头颈鳞癌患者。无结外扩展或切缘阳性者中约三分之一接受辅助全身治疗,该比例逐年下降,且与更差的总生存相关。
要点
- 无结外扩展或切缘阳性患者中约三分之一接受辅助全身治疗,比例逐年下降。
- 2016至2019年年度百分比变化最大,为12.21%(95%CI 3.73%-19.95%)。
- 控制协变量后,无高危特征者接受辅助全身治疗与更差总生存相关。
核心结论
- 无结外扩展和切缘阳性时辅助全身治疗使用仍常见但呈下降趋势,多种患者、提供者和肿瘤因素可能影响其使用。
- 无高危特征时辅助全身治疗与更差总生存相关,提示任何肿瘤学获益可能不足以抵消治疗成本和并发症。
研究设计与样本
- 回顾性队列研究,使用2010至2019年美国国家癌症数据库。
- 纳入接受手术和术后放疗的黏膜头颈鳞状细胞癌患者。
主要发现
- 2010至2019年,无结外扩展或切缘阳性的头颈癌患者中约三分之一接受辅助全身治疗,该比例在整个研究期间下降。
- 年度百分比变化最高出现在2016至2019年,为12.21%(95%CI 3.73%-19.95%)。
- 年轻年龄、男性、西班牙裔、社区项目环境、晚期分期和淋巴血管侵犯增加接受辅助全身治疗的比值。
- 控制协变量后,无结外扩展或切缘阳性者接受辅助全身治疗与更差总生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine trends and survival implications of adjuvant systemic therapy use for lower risk head and neck cancer. STUDY DESIGN: Retrospective cohort study. SETTING: US National Cancer Database, 2010 to 2019. METHODS: Patients with mucosal head and neck squamous cell carcinoma treated with surgery and postoperative radiation therapy were identified. Adjuvant systemic therapy trends in those with and without extranodal extension or positive margins were assessed as annual percent change by JoinPoint analysis. Factors associated with adjuvant systemic therapy and overall survival were assessed with multivariable models and cox proportional hazard models, respectively. RESULTS: From 2010 to 2019, approximately one-third of head and neck cancer patients without extranodal extension or positive margins received adjuvant systemic therapy. This rate decreased throughout the study period, with the highest annual percent change from 2016 to 2019 (12.21%; 95% confidence interval: 3.73%-19.95%). Younger age, male sex, Hispanic ethnicity, community program setting, advanced stage, and lymphovascular invasion increased the odds a patient would receive adjuvant systemic therapy. Adjuvant systemic therapy was associated with inferior overall survival when used in those without extranodal extension or positive margins after controlling for covariates. CONCLUSION: Though decreasing, adjuvant systemic therapy use is still common in the absence of extranodal extension and positive margins, and a variety of patient, provider, and oncologic factors may influence its use. The inferior overall survival after adjuvant systemic therapy in the absence of high-risk features suggests any oncologic benefit may not outweigh the costs and morbidity of the therapy.
引用
- Armstrong AT, Velez-Velez LM, Simpson MC, et al. Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High-Risk Features. Otolaryngol Head Neck Surg. 2023. PMID: 36939584. doi:10.1002/ohn.252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。